跳至主要内容
临床试验/NCT01850758
NCT01850758已完成不适用

A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears

Regenexx, LLC1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Regenexx, LLC
入组人数
50
试验地点
1
主要终点
IKDC Subjective Knee Evaluation Score Change from Baseline

研究概览

简要总结

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months.

Secondary objectives include evaluation of MRI evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

详细描述

Prospective, randomized, controlled to include 25 subjects treated with Regenexx SD and 25 subjects treated with exercise therapy alone with the exercise group crossing over to the injection group at 3 months.

Subjects will have a partial or complete, non-retracted ACL ligament tear as evidenced with MRI.

Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of exercise therapy and take part in follow-up visits for two years following treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection.

The primary endpoint analysis will be conducted once all subjects reach the 3 month endpoint. Subjects will continue to be followed through the 2 year endpoint with data analysis performed at the 1 year and 2 year time points.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Pain, swelling, or functional disability in the affected knee with activity, having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months or unable to return to normal day to day activities by 6 weeks
  • •Physical examination consistent with lax ACL ligament (Anterior Drawer Test)
  • •Abnormal Telos Arthrometer measurement
  • •Positive diagnostic MR imaging of the affected knee with at least 1/3 of the ACL ligament at any area along its length having high signal on MRI PDFS/Fat Sat images.
  • •Full range of motion of the affected knee (other than restriction clearly due to effusion)
  • •Normal range of motion of the non-treated knee
  • •Is independent, ambulatory, and can comply with all post-operative evaluations and visits

排除标准

  • •A massive ACL tear or one that includes more than 2/3'rds of the ligament that's retracted.
  • •Previous surgery to the affected ACL (i.e. previous ACL replacement with an autograft or allograft)
  • •Prior ACL prolotherapy, PRP, corticosteroid injection or other injection therapy within the past three months,
  • •Concomitant meniscus tear or cartilage injury that occurred at the same time as the as the ACL tear and which is considered a pain generator by the treating physician at the time intake into the study (i.e. a meniscus tear or cartilage lesion associated with an active BML).
  • •Concomitant PCL or LCL tears
  • •Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
  • •Quinolone or Statin induced myopathy/ tendinopathy
  • •Kellgren-Lawrence grade 2 or greater knee osteoarthritis
  • •Significant knee extension lag compared to the opposite knee
  • •Symptomatic lumbar spine pathology (e.g. radicular pain)
  • •Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh
  • •Contraindications for MRI
  • •Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site
  • •Condition represents a worker's compensation case
  • •Currently involved in a health-related litigation procedure
  • •Is pregnant
  • •Bleeding disorders
  • •Currently taking anticoagulant or immunosuppressive medication
  • •Allergy or intolerance to study medication
  • •Use of chronic opioid,

研究组 & 干预措施

Exercise Therapy

Active Comparator

Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.

干预措施: Exercise Therapy (Other)

Regenexx SD

Active Comparator

Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.

干预措施: Regenexx SD (Procedure)

结局指标

主要结局

IKDC Subjective Knee Evaluation Score Change from Baseline

时间窗: Change from Baseline to 3 months

The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in IKDC scores.

次要结局

  • Mean IKDC Subjective Knee Evaluation Scores(6, 12 and 24 months)
  • Magnetic Resonance Evaluation of ligament repair(6 months)
  • Incidence of complications and adverse events(24 months)
  • Mean Pain Scales(3, 6, 12 and 24 months)
  • Use of pain medications(3, 6, 12 and 24 months)
  • Incidence of re-injection and surgical revision(24 months)

研究者

发起方
Regenexx, LLC
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验